However, routine testing of advanced lung adenocarcinomas was not recommended until 2011, after the IPASS and EURTAC trials were published and oral EGFR‐TKIs such as erlotinib and gefitinib were approved for treatment of patients with EGFR mutations.1, 2, 3. Here, EGFR is linked to lung adenocarcinoma.